Dicerna Pharmaceuticals, Inc. today announced that it has entered into a definitive agreement with Novo Nordisk under which Novo Nordisk will acquire Dicerna, a biopharmaceutical company focused ...

Novo Nordisk today announced that the acquisition of Dicerna Pharmaceuticals, Inc., announced on 18 November 2021, has been completed. Following the expiration of Novo Nordisk’ s cash tender ...

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) today announced that it has entered into a definitive agreement with Novo Nordisk under which Novo Nordisk will ...

Novo Nordisk A/S (NYSE: NVO) has agreed to acquire Dicerna Pharmaceuticals Inc (NASDAQ: DRNA) for $38.25 per share in cash, representing a total equity value of $3.3 billion and a premium of 80% ...

Novo Nordisk A/S NVO announced a definitive agreement to acquire Massachusetts-based biopharmaceutical company, Dicerna Pharmaceuticals, Inc. DRNA, for a total equity value of approximately $3.3 ...

Novo Nordisk will apply Dicerna Pharmaceuticals’ GalXC™ platform to discover and develop RNA interference (RNAi) therapies for liver-related cardio-metabolic diseases, through a collaboration ...

Novo Nordisk announced the acquisition of Dicerna Pharmaceuticals for $3.3 billion in cash or $38.25 per share, an 80% premium to the closing price on the day prior to the announcement.

Having missed out on Ablynx to Sanofi in 2018, Novo Nordisk has agreed to a $3.3 billion buyout of its RNAi partner Dicerna Pharmaceuticals as part of its search for new growth drivers.

(Reuters) -Danish drugmaker Novo Nordisk has agreed a $3.3 billion cash deal to buy Dicerna Pharmaceuticals which specializes in therapeutics that counteract disease-causing genes, it said on ...

Novo Nordisk (NYSE:NVO) has signed an agreement with Dicerna Pharmaceuticals (NASDAQ:DRNA), under which it will acquire Dicerna for $38.25 per share in cash. The purchase consideration indicating ...

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) today announced that it has entered into a definitive agreement with Novo Nordisk under which Novo Nordisk will acquire Dicerna, a biopharmaceutical ...

Novo Nordisk has been advised by the depositary for the tender offer that a total of approximately 64,946,526 shares of Dicerna’s common stock were validly tendered and not validly withdrawn in ...